DocGo 2025 Q3 Earnings Severe Net Loss Expansion of 752.4% Amid Revenue Decline

Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Monday, Nov 10, 2025 11:20 pm ET1min read
Aime RobotAime Summary

-

reported a $0.28/share Q3 2025 loss (vs. $0.05 profit in 2024) with $70.81M revenue (-48.9% YoY), citing migrant program wind-down and strategic investments.

- Transportation Services drove 70.81M revenue, while Mobile Health Services contributed $20.69M, with corporate segment reporting $0 revenue excluding migrant-related income.

- CEO emphasized core business growth through SteadyMD acquisition and virtual care expansion, targeting 2026 profitability as EBITDA-negative segments improve.

- Zacks assigned a #3 (Hold) rating amid mixed post-earnings performance, reflecting investor uncertainty about short-term recovery despite long-term strategic focus.

DocGo (DCGO) reported Q3 2025 earnings on Nov 10, 2025, . $0.05 profit in 2024) and $70.81M revenue (down 48.9% YoY). , citing migrant program wind-down and strategic investments.

Revenue

DocGo’s third-quarter revenue of $70.81 million was driven by Transportation Services, , while Mobile Health Services accounted for $20.69 million. The Corporate segment reported $0 revenue, . Excluding migrant-related revenue, .

Earnings/Net Income

The company swung to a $0.28 per-share loss in Q3 2025 (vs. $0.05 profit in Q3 2024), . . , underscoring the severity of the financial downturn.

Post-Earnings Price Action Review

, . The mixed performance reflects investor uncertainty about short-term recovery amid management’s long-term optimism.

CEO Commentary

CEO emphasized record volumes in core businesses, driven by long-term medical transportation contracts and the SteadyMD acquisition. Strategic priorities include scaling virtual care and achieving 2026 profitability as EBITDA-negative segments improve.

Guidance

. , .

Additional News

  1. M&A Activity:

    acquired SteadyMD, , to enhance scalability and integrate virtual and in-person services.

  2. Strategic Expansion.

  3. Investor Outlook: Zacks Investment Research assigned DocGo a #3 (Hold) rating, .

DocGo’s Q3 results highlight a challenging transition phase, with significant revenue contraction offset by long-term growth strategies. The acquisition of SteadyMD and focus on core business expansion signal intent to rebuild momentum, though near-term profitability remains uncertain.

Comments



Add a public comment...
No comments

No comments yet